T HE VALUABLE OVERVIEW by Sigitova and colleagues, 1 recently published in Psychiatry and Clinical Neurosciences, has extensively examined biological hypotheses of bipolar disorder (BD), reviewing promising biomarkers for early diagnosis and potential treatments. This comprehensive review can possibly be complemented by growing evidence on the role of uric acid (UA) as a biomarker of BD and related phases, 2, 3 similarly to behavioral abnormalities based on genetically determined disorders, such as Lesch-Nyhan syndrome. 4 UA is a major antioxidant related to the catabolism of adenosine, a neuromodulator with potential antimanic effects. 5 Following the hypothesis of Machado-Vieira et al. postulated in the early 2000s, 5 UA might be considered as a marker of an enhanced turnover, and a reduced neurotransmission, of adenosine in subjects with BD. The hypothesis suggesting a role for UA in BD physiopathology and course was recently supported. Meta-analytic data preliminarily highlighted that UA might represent both a trait and state biomarker of BD. 6 Indeed, UA levels in BD were higher than those in healthy controls (standardized mean difference [SMD] = 0.65) and major depressive disorder patients (SMD = 0.46). Moreover, UA levels were higher in BD manic/mixed phases as compared with depressive ones (SMD = 0.34), suggesting its role as a state biomarker. This finding was also confirmed by a recent observational study, 7 showing an association between bipolar mania and increased UA, after controlling for relevant confounders, such as metabolic profile and oxidative stress parameters. On the other hand, subjects with bipolar depression and those with major depressive disorder shared similar features on UA levels, thus not supporting the utility of UA in differentiating unipolar and bipolar depression. Finally, an implication of UA in manic phases has been supported by a systematic review and meta-analysis 8 of double-blind, randomized clinical trials, exploring the add-on efficacy and tolerability of the purinergic modulator allopurinol, a xanthine oxidase inhibitor. Consistently with the proposed hypothesis, add-on allopurinol showed a small-to-moderate effect in reducing mania symptoms (SMD = −0.34), although this was based on low-quality evidence. For the reasons listed, we believe that UA and purinergic metabolites can be potentially considered biomarkers and promising targets for research on novel therapeutic options for BD.
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